Autres

Creating Drugs at the Speed of Ai Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug CreationTM platform unlocks the potential to accelerate time to clinic and increase the probability of success by … [voir plus]

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs. [voir plus]

Artificial intelligence for new drug design We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. … [voir plus]

#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning … [voir plus]

Bridging Vision & Precision Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a … [voir plus]

Industrializing scientific discovery to radically improve lives. Valence Labs, powered by Recursion, is industrializing scientific discovery to radically improve lives. Our vision is that highly autonomous systems capable of Nobel-worthy insights will usher in a new wave of scientific discovery. Following the acquisition of Valence Discovery by Recursion (NASDAQ: RXRX) … [voir plus]